Skip to content

Sophia Genetics

US · SOPH #3618 by market cap Listed 2021
6.23 -0.45 -6.74%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 6.53 -2.25%
After-hours 6.23 0.00%
8.924.786.232026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SOPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +17.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 1.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 67.4% Better than 81%
Operating margin -91.8% Better than 7%
Net margin -102.2% Better than 7%
Return on equity -110.0% Better than 5%
Return on invested capital -65.1% Better than 4%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -28.0% Better than 20%
6-month return 27.7% Better than 88%
12-month return (ex latest month) 61.9% Better than 88%
Distance below 52-week high 30.6% Better than 42%
Financial Health D+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.0x Better than 55%
Debt to assets 38.7% Better than 28%
Interest coverage -16.0x Better than 11%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 84.6% Better than 80%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -24.12%
1M -10.10%
3M -25.21%
6M +27.93%
YTD +33.40%
1Y +60.15%
3Y +67.92%
5Y -59.68%

Key statistics

Price & volume

Prev close
6.68
Open
6.51
Day range
6.16 - 6.88
Avg price
6.30
Volume
827.72K
Turnover
5.22M
Amplitude
10.75%
52-week range
4.01 - 8.98

Valuation

P/E
-5.32
P/E (TTM)
-5.72
P/B
7.75
EPS
-1.17
Net profit
-100.22M
Net assets
68.87M

Share structure

Market cap
533.65M
Float cap
412.30M
Shares out
85.66M
Float shares
66.18M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-07-23
52-week range 45% of range
4.01 8.98

30.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-11.02M net over the window

Short interest

Shares short
1.15M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Sophia Genetics (SOPH)?

Sophia Genetics last traded at 6.23. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Sophia Genetics's market cap?

About 533.65M.

What is the P/E ratio of Sophia Genetics?

The trailing twelve-month P/E is -5.72. The Valuation tab shows it against the stock's own five-year range.

Does Sophia Genetics pay a dividend?

Sophia Genetics does not currently pay a regular dividend.

Is Sophia Genetics a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 11.50, which implies 84.6% upside from the current price. This is not investment advice.

What is Sophia Genetics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Sophia Genetics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:18 · For reference only, not investment advice and not tailored to your situation.

Sophia Genetics discussion 0 comments

Add a comment